en · de · es · fr · pt
epitalon-notes.peptides1004.com › Data › Analytical Verification And Storage — What the Evidence Shows

Analytical Verification And Storage — What the Evidence Shows

By Editorial Desk · published 2026-01-02 · last reviewed 2026-02-19 · Data

Everything below concerns tetrapeptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2026-02-19. Where a claim depends on a specific study, the study is described rather than over-claimed.

Analytical Verification and Storage

Verification of a sample usually begins with reversed-phase high-performance liquid chromatography, which resolves the peptide from truncated sequences and other impurities and expresses purity as a percentage of total peak area. Mass spectrometry by electrospray ionisation or matrix-assisted laser desorption supplies an independent check, because the measured mass can be compared against the theoretical value for AEDG. Amino acid analysis or tandem mass spectrometry sequencing can confirm residue order. Each of these methods answers a different question: a purity figure does not establish identity, and an identity match does not establish how much of the material is intact peptide.

The molecule is a short, linear, hydrophilic peptide that dissolves readily in water or aqueous buffer. Its principal chemical liabilities are hydrolytic rather than oxidative, since it contains no cysteine, methionine, or tryptophan residues. The aspartate–glycine step is a recognised site for aspartimide formation under mildly acidic or basic conditions, generating isoaspartate and succinimide-related products over time. Desiccated lyophilised powder held at −20 °C is comparatively stable, whereas dilute solutions degrade faster and are best frozen as single-use aliquots rather than thawed repeatedly.

Peptide Identity and Laboratory Handling

Epitalon is a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, abbreviated AEDG. Its molecular formula is C14H22N4O9 and its calculated monoisotopic mass is approximately 390.35 daltons. The compound does not occur naturally as a free peptide; it is produced by solid-phase peptide synthesis. Because it contains two acidic residues and no basic residues, the neutral form carries a net negative charge at physiological pH. This charge profile influences how the peptide behaves in solution and during chromatographic analysis.

Laboratory-grade epitalon is typically supplied as a lyophilized powder. Purity is commonly assessed with reverse-phase high-performance liquid chromatography, often paired with mass spectrometry to confirm molecular identity. Amino acid analysis and peptide mapping can provide additional confirmation of sequence. Certificates of analysis for research materials frequently report purity above 95 percent, although the methods behind such figures vary between suppliers. The absence of a pharmacopeial monograph means that no single standardized assay defines the compound, so reported results depend on the analytical protocol chosen.

Storage recommendations center on limiting moisture, heat, and light. The dry powder is generally kept at minus 20 degrees Celsius, and some suppliers recommend minus 80 degrees for long-term archival. Once dissolved, solutions are usually aliquoted and frozen to avoid repeated freeze-thaw cycles, which can promote aggregation or degradation. Aqueous stability depends on pH and concentration, and buffered saline is often preferred over plain water for biological work. Stability data specific to epitalon remain limited, so general peptide-handling practices are applied by analogy rather than from product-specific validation.

Epitalon at a glance

PropertyValueNotes
Identity confirmationElectrospray or MALDI mass spectrometryObserved mass compared with theoretical 390.35 Da
Purity specification95 percent or greater by RP-HPLCCommon convention for research-grade peptide
Counter-ionAcetate or trifluoroacetateAffects net peptide content of a weighed sample
Solution storage−80 °C as single-use aliquotsRepeated freeze–thaw cycles accelerate loss
Main degradation routeAspartimide formation at Asp-GlyProduces isoaspartate and related species

Research Claims and Evidence Status

Animal and clinical reports appear mainly in Russian-language journals from the 1990s and 2000s, covering endpoints such as melatonin rhythm, lifespan in aged rodents, and retinal function. Many of these papers involve small groups, lack blinding or placebo comparison, and are difficult to retrieve through indexed databases. Review articles published in English generally summarise the claims without reanalysing the underlying data. Because no large randomised trial exists, the clinical importance of these reported effects stays unresolved and is properly described as an open question.

No national medicines regulator has approved epitalon as a therapeutic product. It is generally distributed as a research chemical, and in some jurisdictions selling peptides for human consumption without approval is restricted or prohibited. Certificates of analysis accompanying commercial material vary in which tests are performed, and independent verification of identity and purity is uncommon. Statements about anti-ageing or disease-prevention benefits on vendor pages are marketing claims rather than regulatory findings, a distinction that shapes how the compound is discussed in scientific and popular sources alike.

Related pages on this site

Epitalon Peptide Background and Structure

Interest in epitalon is usually discussed within the broader field of short peptide bioregulators, a category that includes other synthetic di-, tri-, and tetrapeptides studied by the same research group. These compounds share a common rationale: that small fragments of tissue-derived proteins can retain biological activity and can be produced reproducibly. The category as a whole remains outside mainstream pharmacological consensus, and epitalon specifically has a limited presence in independent, non-Russian research literature, which shapes how its evidence base is described.

Epitalon is a synthetic tetrapeptide with the amino acid sequence alanine-glutamate-aspartate-glycine, abbreviated Ala-Glu-Asp-Gly or AEDG. It was developed by the Russian researcher Vladimir Khavinson and colleagues during work on peptide bioregulators derived from the pineal gland. The compound is short enough to be produced by standard solid-phase peptide synthesis and is typically handled as a lyophilized white powder. Its small size distinguishes it from larger pineal peptides such as epithalamin, a complex extract from which the tetrapeptide was conceptually derived.

The four residues give epitalon a molecular formula of C14H22N4O9 and a molecular weight near 390.35 daltons. The presence of two acidic residues, glutamate and aspartate, makes the free peptide strongly acidic, while the alanine and glycine ends provide neutral, nonpolar character. This combination produces a molecule with substantial water solubility. Because there are no cysteine, methionine, or tryptophan residues, the peptide lacks the most common oxidation-sensitive side chains, which simplifies handling compared with many longer peptides.

Laboratory Handling Storage and Analysis

Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection, frequently near 214 nanometers where the peptide bond absorbs. Mass spectrometry, most often with electrospray ionization, confirms the observed molecular mass and helps separate the intact peptide from truncated or modified forms. Amino acid analysis or tandem mass spectrometry can establish residue order. Purity is commonly quoted as an area percentage, yet such values are method-dependent, and comparisons between laboratories require matching column, gradient and detection wavelength.

Laboratory handling begins with dissolution of the lyophilized powder in water or a suitable aqueous buffer. The dry solid is the more stable form, so stock solutions are generally prepared only when required and kept cold afterwards. Repeated freezing and thawing of a solution is avoided because it encourages aggregation and gradual loss of the intact chain. Diluents and containers are selected to limit adsorption of a short peptide onto plastic surfaces and to reduce microbial growth in aqueous preparations.

Epitalon Background and Discovery

Published studies on epitalon are dominated by a small number of research groups, and independent replication in other laboratories remains limited. Proposed mechanisms include activation of telomerase and modulation of melatonin rhythms, but the evidence for either rests mainly on cell cultures and animal models. Whether the peptide produces comparable effects in humans is an open question, and the absence of large controlled trials means the literature is best read as exploratory rather than settled.

Epitalon is a synthetic four-amino-acid peptide with the sequence alanine-glutamate-aspartate-glycine, commonly abbreviated AEDG. Its molecular formula is C14H22N4O9, and its calculated molar mass is approximately 390.35 grams per mole. The compound is a short fragment related to a peptide fraction isolated from bovine pineal gland extracts, and it is normally supplied as a lyophilised powder intended for laboratory research. It is not a registered pharmaceutical product in most countries.

The peptide emerged from research carried out in Saint Petersburg from the late 1980s onward, where investigators searched for shorter active fragments of a pineal preparation known as epithalamin. The name epitalon was chosen to reflect that parent extract. Early reports described effects on neuroendocrine markers and on the lifespan of laboratory animals. Much of that work appeared in Russian-language journals, with English translations following later, which affects how readily the original protocols can be assessed by outside groups.

Supporting material

== Research and development == In November 2013, Discovery Laboratories began its phase II clinical program of aerosolized KL4 since U.S. Food and Drug Administration (FDA) had cleared the investigational new drug (IND) application. The phase II consists of two steps to evaluate the safety and tolerability of the drug and determine the optimal dose for premature infants with respiratory distress syndrome (RDS) In October 2013, Discovery Laboratories received the agreement of updating Surfaxin (lucinactant) Intratracheal Suspension from the U.S. Food and Drug Administration (FDA) to prevent respiratory distress syndrome (RDS) in premature infants. In September 2012, Discovery Laboratories started the four research projects to explore the KL4 surfactant technology for acute lung injury (ALI). These projects are funded through government-sponsored, biodefense-related initiatives under the Project Bioshield Act of 2004 and the Pandemic and All-Hazards Preparedness Act of 2006.

insertion sequence (IS) Also insertion element or simply insert. Any nucleotide sequence that is inserted naturally or artificially into another sequence. The term is used in particular to refer to the part of a transposable element that codes for those proteins directly involved in the transposition process, e.g. the transposase enzyme. The coding region in a transposable insertion sequence is usually flanked by short inverted repeats, and the structure of larger transposable elements may include a pair of flanking insertion sequences which are themselves inverted.

Nixon and Kissinger played a "good cop-bad cop" routine with Dobrynin, with Nixon acting the part of the petulant president at the end of his patience with North Vietnam, while Kissinger acted as the reasonable diplomat anxious to improve relations with the Soviet Union, saying to Dobrynin in May 1969 that Nixon would "escalate the war" if the Soviet Union "didn't produce a settlement" in Vietnam. At another meeting in 1969, Kissinger warned Dobrynin that "the train has just left the station and is now headed down the track", saying the Soviet Union better start pressuring North Vietnam now before Nixon did something truly reckless and dangerous. The attempt at "linkage" failed as the Soviet Union did not pressure North Vietnam and instead Dobrynin told Kissinger that the Soviets wanted better relations with the United States regardless of the Vietnam War. After the failure of the "linkage" attempt, Nixon became more open to the alternative strategy suggested by the Defense Secretary Melvin Laird who argued that the burden of the war should be shifted to the South Vietnamese, which was initially called "de-Americanization" and which Laird renamed Vietnamization because it sounded better.

Sources: en.wikipedia.org

Notes from published material

=== United States === The United States Code of Federal Regulations standard for blue cheese specifies a minimum milkfat content of 50 percent, and maximum moisture of 46 percent. Optional ingredients permitted include food coloring to neutralize the yellowish tint of the cheese, benzoyl peroxide bleach, and vegetable wax for coating the rind.

Sprigg urged Letsie I to negotiate Masopha's unconditional surrender, until a force of Cape Mounted Riflemen (CMR) could arrive to assist him. Letsie I replied that this was unrealistic, as most of the Basuto, including his sons, had rallied behind Masopha. Letsie and his armed retinue, returned to their village on 19 August after several days of negotiations, fearing that they would be ambushed if they remained outside Thaba Bosiu any longer. In a last ditch effort to prevent an uprising, Sprigg visited Letsie I in person. Letsie I then held another pitso—under Sprigg's new terms the rebel chiefs were to appear in court where they would receive a token fine, pledge to compensate those whose property they had seized, and comply with the gun regulations. Masopha remained defiant and held an assembly of his own, where he and Lerotholi began to prepare for war. Masopha believed that the Cape's troops had proved themselves to be incompetent during the suppression of Moorosi's revolt. He was further encouraged by rumors that the British would refuse to reinforce the Cape, and by the British defeat at the Battle of Isandlwana a year prior.

semiconservative replication The standard mode of DNA replication that occurs in all living cells, in which each of the two parental strands of the original double-stranded DNA molecule are used as template strands, with DNA polymerases replicating each strand separately and simultaneously in antiparallel directions. The result is that each of the two double-stranded daughter molecules is composed of one of the original parental strands and one newly synthesized complementary strand, such that each daughter molecule conserves the precise sequence of information (indeed the very same atoms) from one-half of the original molecule. Contrast conservative replication and dispersive replication.

Laron syndrome (LS), also known as growth hormone insensitivity or growth hormone receptor deficiency (GHRD), is an autosomal recessive disorder characterized by a lack of insulin-like growth factor 1 (IGF-1; somatomedin-C) production in response to growth hormone (GH; hGH; somatotropin). It is usually caused by inherited growth hormone receptor (GHR) mutations. The syndrome is named after the scientist Zvi Laron who first discovered the syndrome in 1966. Affected individuals classically present with short stature between −4 and −10 standard deviations below median height, obesity, craniofacial abnormalities, micropenis, low blood sugar, and low serum IGF-1 despite elevated basal serum GH. LS is a very rare condition with a total of 250 known individuals worldwide. The genetic origins of these individuals have been traced back to Mediterranean, South Asian, and Semitic ancestors, with the latter group comprising the majority of cases. Molecular genetic testing for growth hormone receptor gene mutations confirms the diagnosis of LS, but clinical evaluation may include laboratory analysis of basal GH, IGF-1 and IGFBP levels, GH stimulation testing, and/or GH trial therapy. People with LS are unresponsive to growth hormone therapy; the disease is instead treated mainly with recombinant IGF-1, Mecasermin. Evidence has suggested that people with Laron syndrome have a reduced risk of developing cancer and diabetes mellitus type II, with a significantly reduced incidence and delayed age of onset of these diseases compared to their unaffected relatives.

Sources: en.wikipedia.org

Further detail

Patients with CSF leaks have been noted to have very low or even negative opening pressures during lumbar puncture. However, patients with confirmed CSF leaks may also demonstrate completely normal opening pressures. In 18–46% of cases, the CSF pressure is measured within the normal range. Analysis of spinal fluid may demonstrate lymphocytic pleocytosis and elevated protein content or xanthochromia. This is hypothesized to be due to increased permeability of dilated meningeal blood vessels and a decrease of CSF flow in the lumbar subarachnoid space.

== External links == Creatine+Kinase,+MM+Form at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Human CKM genome location and CKM gene details page in the UCSC Genome Browser. Overview of all the structural information available in the PDB for UniProt: P06732 (Creatine kinase M-type) at the PDBe-KB.

== Function == The family of natriuretic peptides elicit a number of vascular, renal, and endocrine effects that are important in the maintenance of blood pressure and extracellular fluid volume. These effects are mediated by specific binding of the peptides to cell surface receptors in the vasculature, kidney, adrenal, and brain.

== Gastropod mucus == Mucus is the viscoelastic, biological secretions from gastropods like snails and slugs. Gastropod mucus serves as a lubricant and survival mechanism, facilitating movement on wet surfaces and preventing dehydration. These functions are attributed to the unique cross-linking and electrostatic interactions as well as the combination of glycoproteins, amino acids, and divalent metal ions, gastropod mucus, that allow it to adhere to surfaces even in wet environments.

== History == Relief Therapeutics was founded in 2013 by Gael Hédou with the aim of developing new treatments for diseases with high unmet needs. The company today considers itself the successor to Mondobiotech, which was founded in 2000 by Fabio Cavalli and Dorian Bevec. Mondobiotech began research into Vasoactive intestinal peptide (VIP), a naturally occurring substance in humans that was first identified in the 1970s. They were granted US and European patents for a synthetic version of VIP known as aviptadil in 2006. On June 23, 2013, Mondobiotech merged with Italian pharmaceutical company Pierrel Research International to form a new Contract research organization known as Therametrics. On July 14, 2016, Therametrics merged with Relief Therapeutics to form Relief Therapeutics Holdings AG, which inherited all patents related to aviptadil.

Sources: en.wikipedia.org

Frequently asked questions

Which method confirms epitalon identity?

Mass spectrometry provides the identity check, because the observed mass is compared with the theoretical mass of the AEDG sequence. Chromatography separates and quantifies impurities but does not by itself prove which peptide is present. The two techniques are normally used together.

Does the counter-ion change the stated amount?

Yes. Trifluoroacetate and acetate ions remain associated with the peptide after purification, so a weighed quantity of powder contains less peptide than the nominal mass suggests. Certificates that report net peptide content rather than raw weight are more directly comparable between suppliers.

How should epitalon solutions be kept?

Dilute aqueous solutions are less stable than the dry powder and are usually aliquoted and frozen to avoid repeated freeze–thaw cycles. Lyophilised material is best stored desiccated at −20 °C, protected from light. Working solutions are typically prepared fresh from a frozen aliquot.

What is epitalon made of?

Epitalon is a synthetic tetrapeptide built from four amino acids: alanine, glutamate, aspartate, and glycine. It is not extracted from a natural source but made in the laboratory by chemical synthesis. Its short length makes it relatively straightforward to produce at high purity.

Network